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Abstract 
 
 TRAIL is involved in immune tumor surveillance and is considered a 
promising anti-cancer agent owing to its limited side effects on healthy cells. 
However, some cancer cells display resistance, or become resistant to TRAIL-
induced cell death. Hyperthermia can enhance sensitivity to TRAIL-induced cell 
death in various resistant cancer cell lines, including lung, breast, colon or 
prostate carcinomas. Mild heat shock treatment has been proposed to restore 
Fas ligand or TRAIL-induced apoptosis through c-FLIP degradation or the 
mitochondrial pathway. We demonstrate here that neither the mitochondria nor c-
FLIP degradation are required for TRAIL-induced cell death restoration during 
hyperthermia. Our data provide evidence that insolubilisation of c-FLIP, alone, is 
sufficient to enhance apoptosis induced by death receptors. Hyperthermia 
induced c-FLIP depletion from the cytosolic fraction, without apparent 
degradation, thereby preventing c-FLIP recruitment to the TRAIL DISC and 
allowing efficient caspase-8 cleavage and apoptosis. Hyperthermia-induced c-
FLIP depletion was independent of c-FLIP DED2 FL chain assembly motif or 
ubiquitination-mediated c-FLIP degradation, as assessed using c-FLIP point 
mutants on lysine 167 and 195 or threonine 166, a phosphorylation site known to 
regulate ubiquitination of c-FLIP. Rather, c-FLIP depletion was associated with 
aggregation, since addition of glycerol not only prevented loss of c-FLIP from the 
cytosol but enabled c-FLIP recruitment within the TRAIL DISC inhibiting thus 
TRAIL-induced apoptosis during hyperthermia. 
 
 Altogether our results demonstrate that c-FLIP is a thermosensitive protein 
whose targeting by hyperthermia allows restoration of apoptosis induced by TNF 
ligands, including TRAIL. Our findings suggest that combining TRAIL agonists 
with whole body or localized hyperthermia may be an interesting approach in 
cancer therapy.  
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Introduction : 
 
 TRAIL holds promise in the clinic owing to its anti-tumoral selectivity.1 
Evaluation of TRAIL in patients has however proved less efficient than 
anticipated.2 Amongst the regulatory mechanisms that may explain TRAIL 
resistance, c-FLIP, which is highly expressed in primary tumors and often 
associated with bad prognosis,3, 4, 5 is likely to play the most important role. 
Targeting c-FLIP has clearly emerged as an important issue for cancer therapies. 
So far, three isoforms have been described. The long isoform, c-FLIPL, 
composed of two death effector domains (DED) and a caspase-like domain 
devoid of the prototypic catalytic cysteine contained in pro-caspases,6 and two 
short isoforms, c-FLIPS and c-FLIPR, mainly composed of the two DEDs.
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Regardless of the isoform, c-FLIP proteins are co-recruited within the DISC of 
death domain (DD)-containing receptors of the TNF superfamily and prevent the 
release of active caspase-8 to the cytosol, inhibiting apoptosis induced by these 
death receptors.8, 9 
 
 Expression levels of c-FLIP proteins are regulated both transcriptionally and 
post-transcriptionally. At the transcriptional level, c-FLIP isoforms are repressed 
by transcription factors including E2F1 or c-Myc,10, 11 or induced by NF-kB.12, 13 
Regulation of c-FLIP expression by NF-kB plays a central role in protecting cells 
from TNF-induced cell death.14 This pro-inflammatory signaling pathway 
contributes to sustained expression of c-FLIP in primary tumors and confers 
resistance to apoptosis-induced by death receptors.15, 16 At the post-translational 
level, c-FLIP proteins are regulated through the ubiquitin-proteasomal pathway. 
Ubiquitination of c-FLIP on lysines 167 or 195 induces its degradation by the 
proteasome.17, 18 Phosphorylation of c-FLIP can also lead to regulation of c-FLIP 
ubiquitination and degradation. Activation of PKC induces c-FLIP 
phosphorylation on serine 193 and inhibits c-FLIPs ubiquitination and 
degradation.19 ROS can also induce c-FLIP phosphorylation on threonine 166, 
leading to c-FLIP ubiquitination on lysine 167 and degradation by the 
proteasome.18 Several ubiquitin ligases contribute to c-FLIP ubiquitination 
including itch, c-Cbl and AIP4.20, 21, 22 Consistent with the increasing body of 
evidence demonstrating that a large number of stimuli lead to c-FLIP degradation 
and restoration of apoptosis induced by death receptors,7 hyperthermia has 
recently been proposed to restore TRAIL pro-apoptotic signaling through 
ubiquitination of c-FLIP on K195.17  
 
 Herein, we provide evidence that proteosomal-mediated degradation of c-
FLIP, albeit induced during hyperthermia, is not required for sensitization or 
restoration of TRAIL-induced cell death. Instead, our findings demonstrate that 
both c-FLIP isoforms are thermolabile proteins that aggregate during 
hyperthermia. As a consequence, c-FLIP proteins are not available in the cytosol 
and their recruitment within the TRAIL DISC is impaired, which allows efficient 
initiator caspase activation.   
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Results : 
 
Hyperthermia restores TRAIL-induced apoptosis in a mitochondrial-
independent manner.  
 
 Hyperthermia restores TRAIL-induced apoptosis in tumor cells17, 23, 24 but 
not in normal cells.25 In line with these findings, incubating resistant cancer cell 
lines of various origin for 1 hour at 42°C (HS) in the presence of TRAIL followed 
by subsequent incubation at 37°C for 5 hours (Figure 1a), significantly increased 
apoptosis triggered by TRAIL as compared to a 6 hours incubation time at 37°C 
(Figure 1b). Incubation of the cells during the first hour at milder temperature, ie 
39°C, or at 0°C failed to do so (Supplementary Figure 1a and b). As expected, 
incubating cells for 1 h at 42°C was sufficient to induce a time-dependent up-
regulation of inducible HSPs including HSP27, αB-crystallin, HSP70 or HSP110 
(Supplementary Figure 1c), phosphorylation of HSP27 on serine 15, 78 and 82, 
translocation of HSP27 into the non-ionic detergent insoluble fraction and to 
increase protein ubiquitination (Supplementary Figure 1d). However, restoration 
of TRAIL pro-apoptotic activity by HS (Figure 1b) was not correlated with steady 
state differential expression levels of HSPs (Supplementary Figure 2b) or TRAIL 
receptors but to some extent with c-FLIP expression levels (Supplementary 
Figure 2a and b). Likewise, regardless of their initial sensitivity to TRAIL 
(Supplementary Figure 2c), cells expressing high amounts of c-FLIP were more 
responsive to TRAIL during HS (Figure 1b) than cells expressing low levels 
(Supplementary Figure 2). 
  
 To understand the molecular mechanisms underlying the gain of function 
during hyperthermia, we decided to use the resistant mammary carcinoma cell 
line MDA-MB-231 as a model cell line. Cell death induced by TRAIL after a HS, 
was mainly driven by caspases since the pan-caspase inhibitor z-VAD totally 
abrogated apoptosis induced by TRAIL (Figure 1c) and rescued MDA-MB-231 
clonogenic growth after TRAIL stimulation (Figure 1d). As evidenced by 
immunoblotting, hyperthermia enhanced initiator caspase-8, -9 and -10 
processing, as compared to control conditions (37°C), both in the cytosolic and 
the membrane-enriched fractions (Figure 1e). Accordingly, higher amounts of 
RIP and PARP cleaved products were detected in HS samples (Figure 1e). 
Caspase-3, caspase-8 and caspase-9 activation was increased by more than 2 
fold after hyperthemia (Figure 1f). Consistent with this increase, hyperthermia 
was also able to enhance Fas ligand-induced apoptosis, but failed to increase 
apoptosis induced by the PKC-inhibitor staurosporine (Supplementary Figure 
3a). This result suggests that the mitochondrial pathway is likely dispensable to 
restore TRAIL-induced cell death during HS. To test this hypothesis, caspase-9 
or BID were silenced. While BID silencing attenuated TRAIL-induced apoptosis in 
MDA-MB-231 cells at 37°C, it failed to inhibit apoptosis induced by TRAIL after a 
HS (Figure 1g). Loss of caspase-9 had no effect on in these cells, irrespective of 
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the temperature (Figure 1g). Consistent with a lack of requirement for 
mitochondrial activation, ectopic expression of Bcl-xL only slightly attenuated 
TRAIL-induced apoptosis during HS as compared to Mock infected cells (Figure 
1h). Moreover, restoration of TRAIL-induced apoptosis by HS was as efficient in 
the Bax-deficient prostate carcinoma cell line DU145 (Figure 1b), as in parental 
MDA-MB-231 cells pre-incubated with Bax channel blockers (Supplementary 
Figure 3b). By contrast and as expected, caspase-8 silencing completely 
abrogated apoptosis induced by TRAIL both at 37°C and after HS (Figure 1i), 
indicating that reactivation of the mitochondrial pathway is dispensable for TRAIL 
signaling during HS. 
 
 
Hyperthermia impedes c-FLIP recruitment to the TRAIL DISC. 
  
 Since the mitochondrial pathway is not a prerequisite for HS and TRAIL 
synergistic effect, and because it has been proposed that HS may act at the level 
of plasma membrane,26 we decided to analyze TRAIL DISC composition during 
and after HS. As shown Figure 2a, TRAIL DISC formation and composition were 
significantly different in cells incubated at 37°C as compared to cells incubated at 
42°C. Strikingly, while c-FLIP was co-recruited with caspase-8 within the TRAIL 
DISC at 37°C, it was not recruited at 42°C, even when cells were allowed to 
recover from the HS at 37°C (Figure 2a). Consistently, a loss of c-FLIP/caspase-
8 interaction was detected after caspase-8 immunoprecipitation in cells 
stimulated with TRAIL in HS condition (Figure 2b). In line with the gain of 
caspase activation and apoptosis induced by TRAIL after a HS, we observed an 
increase in caspase-8 and caspase-10 processing within the DISC, 120 minutes 
after TRAIL stimulation, and the cleavage of RIP1 (Figure 2).  
 
 HSPs inhibit apoptosis through their ability to interfere with mitochondria.27 
However, a report suggested that HSP90 confers resistance to TRAIL through its 
ability to interact with c-FLIP and to increase c-FLIP recruitment within the 
DISC.28 HSP90 could be detected at 37°C consistent with c-FLIP recruitment 
(Figure 2a). However, at 42°C and therefore in the absence of c-FLIP, albeit to a 
lesser extent, HSP90 was still detected in the DISC (Figure 2a). Moreover 
HSP90 was not observed at 37°C in the caspase-8 pull-down despite the 
presence of c-FLIP, but was detected 5 and 15 minutes after TRAIL stimulation 
at 42°C, a condition in which little c-FLIP remained associated with caspase-8 
(Figure 2b). Contrary to HSP90, however, recruitment of HSP27 was consistently 
found in the TRAIL DISC at 42°C but not at 37°C (Figure 2b), and no HSP70 
could be detected in the DISC, irrespective of the temperature (not shown).  
 
 To sort out whether the presence of HSP27 or HSP90 within the DISC 
might be relevant, these inducible HSPs were silenced. While silencing of HSP27 
enhanced TRAIL both at 37°C and 42°C, silencing of HSP70, HSP90α or 
HSP90β had no significant effect, irrespective of the temperature (Supplementary 
Figure 3c and not shown). Silencing simultaneously both isoforms of HSP90, 
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however, attenuated apoptosis induced by TRAIL during HS but not at 37°C 
(Supplementary Figure 3c and d). HSP90 is a chaperone of RIP1, and is known 
to stabilize this kinase.29 To exclude the possibility that the effects of HSP90α/β 
silencing might require RIP1, the kinase was silenced. Unlike HSP90α/β, 
silencing of RIP1 was unable to alter TRAIL-induced cell death during HS 
(Supplementary Figure 3d), suggesting that HSP90's regulatory properties are 
independent of RIP1. Analysis of caspase activation by immunoblotting in MDA-
MB-231 cells silenced for HSP27, HSP90α/β or RIP1 demonstrated that these 
proteins are unable to regulate early events of TRAIL-induced cell death during 
HS (Supplementary Figure 3e). Neither caspase-8 nor c-FLIP cleavage was 
altered in cells lacking HSPs or RIP1, irrespective of the temperature. However, 
as expected, in cells silenced for HSP27, activation of caspase-9 and caspase-3 
was significantly increased upon TRAIL stimulation, both at 37 and 42°C 
(Supplementary Figure 3e), indicating that HSP27 mainly inhibits TRAIL signaling 
at the mitochondrial level. Our results show that HSPs are not directly involved in 
regulating HS-induced TRAIL sensitization at the DISC level. 
  
Hyperthermia induced c-FLIP insolubilisation occurs in an ubiquitination- 
and phosphorylation-independent manner and is not regulated c-FLIP 
DED2 chain assembly domain. 
 
 Hyperthermia has been proposed to induce ubiquitination-dependent c-
FLIP degradation through the proteasome, allowing restoration of TRAIL- and 
mapatumumab-induced cell death.17 In MDA-MB-231 stimulated with TRAIL 
during HS c-FLIP isoforms remain highly expressed for up to 2 hours as 
evidenced in whole cell lysates (Figure 3a). We thus hypothesized that 
impairment of c-FLIP recruitment to TRAIL DISC during HS (Figure 2) is unlikely 
due to its mere degradation by the proteasome. In line with our hypothesis, while 
c-FLIP levels dropped after TRAIL treatment during HS in the detergent soluble 
fraction (Figure 3b), c-FLIP rapidly accumulated in the insoluble fraction (Figure 
3b). Interestingly, caspase-8, caspase-10 and FADD were also found in the 
insoluble fraction. Yet, contrary to c-FLIP, a large proportion of caspase-10 and 
FADD, and to a lesser extent of caspase-8, remained in the soluble fraction 2 h 
after TRAIL stimulation (Figure 3b). Its high susceptibility to insolubility, most 
likely rendered c-FLIP unavailable for DISC recruitment and thus contributed to 
TRAIL-induced apoptosis restoration during HS. Accordingly, silencing of c-FLIP 
alone was sufficient to restore TRAIL-sensitivity to similar extent as cells exposed 
to a HS (Figure 3c), even at low TRAIL concentrations (Figure 3d). On the other 
hand, increasing c-FLIP levels, irrespective of the isoform, inhibited TRAIL-
induced cell death, both at 37°C or after a HS (Figure 3e). The increase of c-FLIP 
expression in these cells was sufficient to maintain enough c-FLIP levels within 
the cytosol during the course of the HS (Figure 3f), and to inhibit TRAIL DISC 
formation and apoptosis (Figure 3g and e, and Supplementary Figure 4a). 
 
 To exclude the possibility that loss of c-FLIP in the detergent insoluble 
fraction during HS required ubiquitination-mediated c-FLIP degradation,18, 30 point 
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mutants targeting lysine 167 and 195 or threonine 166 were generated, and 
stably expressed in MDA-MB-231 cells, to monitor c-FLIP solubility 
(Supplementary Figure 4b). Like WT c-FLIP, ubiquitinylable-deficient and 
phosphorylation c-FLIP mutants translocated to the detergent insoluble fraction 
upon HS, indicating that neither ubiquitination, nor regulation of ubiquitination 
through c-FLIP phosphorylation contributed to c-FLIP insolubility upon HS. 
Lysine 106 and serine 193 c-FLIP mutants were used here as negative controls 
for proteosomal mediated degradation.18, 19 Regardless of the point mutation, c-
FLIP mutants were as efficient as WT c-FLIP in inhibiting TRAIL-induced cell 
death during HS (not shown), even after a 2 h incubation time at 42°C 
(Supplementary Figure 4c). Similar to WT c-FLIP, most of these mutants were 
expressed at high levels in MDA-MB-231 cells and a large proportion remained in 
the cytosol 60 minutes after HS, explaining their ability to inhibit TRAIL-induced 
cell death. Consistent with the demonstration that c-FLIP ubiquitination-mediated 
degradation is not required for depletion of c-FLIP from the cytosol, pre-
incubation of MDA-MB-231 cells in the presence of MG132 failed to restore c-
FLIP expression in the soluble fraction, regardless of de novo protein synthesis 
(Supplementary Figure 4d). However, inhibition of the proteasome by MG132 led 
to accumulation of c-FLIP in the insoluble fraction, demonstrating that c-FLIP 
degradation occurs after its depletion from the cytosol. Insolubilisation of c-FLIP 
was also independent of c-FLIP DED2 chain assembly motif, since the two chain 
assembly motif mutants (F114G and F114G/L115G)31, 32 were as efficiently 
depleted from the cytosolic fraction as WT c-FLIP (Supplementary Figure 5a). At 
the contrary, depletion of FL114/115G c-FLIP mutant was even more 
pronounced than WT c-FLIP during HS. Interestingly, this mutant was less 
efficient than WT c-FLIP in inhibiting TRAIL-induced cell death upon HS 
(Supplementary Figure 5b), again indicating that depletion of c-FLIP from the 
cytosol, alone, is sufficient to restore TRAIL-induced cell death. 
 
Restoration of c-FLIP in the cytosol enables c-FLIP recruitment to TRAIL 
DISC and inhibits apoptosis induced by TRAIL during HS.   
 
 Translocation of c-FLIP during HS was also found in other tumor cell lines 
of various origin (Figure 4a). As observed in MDA-MB-231, disappearance of c-
FLIP from the soluble fraction in these cells was always more efficient than 
depletion of FADD, RIPK1, caspase-8 or caspase-10, suggesting that enough 
DISC component remains in the cytosol to allow efficient TRAIL-induced cell 
death in the absence of c-FLIP. In order to determine whether the mere increase 
in temperature, but not sequestration of c-FLIP into subcellular compartments 
induced or not through HS-mediated MAPK signalling, is sufficient to induce c-
FLIP aggregation and loss from the cytosol, cell lysates obtained from 
unstimulated MDA-MB-231 cells were incubated at 0°C, 37°C or 42°C for the 
indicated period of time, then centrifuged to separate NP40 soluble and insoluble 
fractions (Figure 4b) and samples were analyzed by immunoblotting. In cell 
extracts incubated at 42°C, c-FLIP content decreased in the soluble fraction in a 
time dependent-manner to accumulate in the insoluble fraction (Figure 4c). As 
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expected, incubation of cell lysates at 0°C or 37°C for 60 minutes failed to induce 
c-FLIP depletion from the cytosolic fraction. Insolubilisation of c-FLIP, but also of 
initiator caspases, was most likely triggered through protein aggregation since 
addition of increasing amounts of glycerol in before incubation at 42°C reduced, 
in a dose dependent manner, the amount of c-FLIP and caspase-8 present in the 
insoluble fraction and restored significant c-FLIP protein content in the cytosolic 
fraction (Figure 4d). Addition of glycerol on intact MDA-MB-231 or HCT116 cells 
prior to incubation at 42°C also inhibited HS-induced c-FLIP aggregation as 
evidenced by the increase of c-FLIPL in the cytosolic fraction (Figure 4e and f). 
Since glycerol is able to prevent loss of c-FLIP from the cytosol we speculated 
that it might protect, at least partially, tumor cells from TRAIL-induced cell death 
after a HS. To address this question, MDA-MB-231 cells were incubated for 60 
minutes in the presence of increasing amounts of glycerol before stimulation with 
TRAIL at 42°C. Analysis of apoptosis induced in these conditions indicates that 
addition of glycerol prior stimulation protected cells from TRAIL-induced 
apoptosis during HS (Figure 4g) and restored c-FLIP recruitment to the TRAIL 
DISC (Figure 4h). Our results provide thus evidence that restoration of death 
receptor-induced cell death by hyperthermia is essentially mediated through c-
FLIP aggregation.   
 
DISCUSSION : 
 
 Hyperthermia was first demonstrated to restore cell death induced by 
TNFα in the late 80’s.33, 34 Only recently has hyperthermia been successfully 
exploited in the clinic with TNFα to treat limb soft tissue sarcomas with high 
response rates,35 or locally advanced cancers.36 Besides TNFα, hyperthermia 
can also promote Fas ligand and TRAIL-induced apoptosis.25, 37, 38 Accordingly, 
we show here that hyperthermia restores TRAIL pro-apoptotic signaling in a large 
panel of tumor cell lines. Yet, contrary to previous demonstrations pointing to a 
contribution of mitochondria,37, 39, 40, 41 our findings clearly demonstrate that the 
mitochondrial pathway is not a prerequisite since neither caspase-9-, Bid- or bax-
deficiency nor Bcl-xL over-expression compromised TRAIL-induced cell death 
during HS. Lack of apparent contribution of caspase-9, in our settings, as 
opposed to Bid at 37°C is most likely due to differential contribution of other 
mitochondrial pro-apoptogenic factors such as Smac/Diablo, whose release in 
the cytosol was shown to play an important contribution for TRAIL-induced cell 
death in MDA-MB-231 cells 42. Likewise, XIAP but not caspase-9 inhibition has 
recently been demonstrated to play a role in regulating TRAIL-induced apoptosis 
in HCT116 cells, described as type II cells43.  
  
 Irrespective of mitochondrial pro-apoptogenic factors, our results 
demonstrate that inhibition of c-FLIP recruitment within the TRAIL DISC is the 
main mechanism through which hyperthermia restores TRAIL-induced cell death. 
Accordingly, loss of c-FLIP recruitment within the DISC was always associated 
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with increased activation of initiator caspases. Over-expression of c-FLIP alone 
or inhibition of c-FLIP aggregation, using glycerol, was sufficient to restore c-FLIP 
recruitment within the DISC and to compromise TRAIL-induced apoptosis during 
HS. Moreover, c-FLIP silencing, alone, was sufficient to phenocopy the effects of 
HS, and combining c-FLIP silencing and HS induced no additional gain of 
function.  
 
 c-FLIP is probably the most important regulator of apoptosis induced by 
death receptors.6 This caspase-8 inhibitor is highly regulated in normal and tumor 
cells,44, 45 and highly susceptible to a plethora of compounds, rendering c-FLIP 
an interesting target for cancer therapy.7, 46 Hyperthermia has recently been 
proposed to enhance TRAIL- and mapatumumab-induced cell death through 
FLIP degradation.17 While our results are in full agreement with the finding that c-
FLIP is the main regulator targeted by hyperthermia allowing restoration of TRAIL 
sensitivity in resistant tumor cells, our data suggest that loss of c-FLIP within the 
TRAIL DISC is however not a direct consequence of its degradation, but rather of 
its aggregation and thereby its disappearance from the cytosol. Loss of c-FLIP 
from the cytosol was evidenced almost as early as 5 minutes after HS, much 
earlier than the onset of c-FLIP cleavage or c-FLIP degradation that was almost 
not observed in our settings. Depletion of c-FLIP from the cytosol also coincided 
with the loss of c-FLIP binding to caspase-8 after TRAIL DISC formation. 
Contrary to c-FLIP, however, caspase-8 was still recruited at 42°C, consistent 
with the gain of pro-apoptotic function afforded by short incubation of the cancer 
cells at 42°C in the presence of TRAIL.  
 
 Moreover, despite the fact that the ubiquitin-proteasomal pathway emerges 
as an important regulator of c-FLIP expression in tumor cells,47 our results 
demonstrate that neither phosphorylation or ubiquitination of c-FLIP nor inhibition 
of the proteasome inhibited c-FLIP depletion from the cytosol during 
hyperthermia, indicating that ubiquitination-mediated proteosomal degradation of 
c-FLIP is not required for its depletion from the cytosol.  
 
 Our results show that depletion of c-FLIP from the cytosol and its recovery 
in an insoluble cellular fraction after a heat shock is most likely triggered by its 
aggregation. Hyperthermia is known to induce protein aggregation, leading 
eventually to cell death.48, 49 In agreement with these findings, disappearance of 
c-FLIP but also, to a lesser extent, of initiator caspases including caspase-8 and 
caspase-10 from the non ionic detergent soluble fraction after hyperthermia was 
detected in all the tumor cell lines studied. However, contrary to the caspase-8 or 
the caspase-10, insolubilisation of c-FLIP led to full disappearance of the protein 
from the cytosol suggesting that c-FLIP may be more thermolabile than caspase-
8 or caspase-10, or that complete depletion induced by HS is due to lower 
expression levels of c-FLIP, as compared to caspase-8 or FADD32. Preferential 
depletion of c-FLIP was not due to its DED2 chain assembly motif, two amino 
acids found to be essential for FADD binding and recruitment to the TRAIL DISC 
31, 32.  
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 Keeping in mind that the amounts of c-FLIPs are most of the time much 
lower than caspase-8  32 or that c-FLIP recruitment within the TRAIL DISC is  5 to 
10 times lower than caspase-8 31, 50, and that at equivalent concentration, 
caspase-8, like FADD, as shown by the use of recombinant GST-fused proteins 
(Supplementary Figure 6a), are found as efficiently as c-FLIP in the insoluble 
fraction of the bacterial cell extracts after a heat shock, « preferential » loss of c-
FLIP from the cytosolic fraction is likely to be due, at least in part, to its low 
intracellular steady state level. Yet, it can’t be excluded that in addition, its higher 
thermolability, as predicted from its amino acid sequence51 (Supplementary 
Figure 6b) might also play a role.  
 
 Whatsoever, addition of glycerol, a compound shown to inhibit protein 
aggregation,49 before hyperthermia prevented, not only the loss of capase-8 and 
FADD from the cytosolic fraction but also the loss of c-FLIP, enabling its 
recruitment within the DISC and conferring partial protection to TRAIL-induced 
cell death. 
 
 Altogether our results provide the first demonstration that aggregation of c-
FLIP induced by hyperthermia, but not degradation, impairs c-FLIP recruitment to 
TRAIL DISC and thus enhance or restores TRAIL-induced cell death in resistant 
cells through depletion of cytosolic c-FLIP reservoir. Keeping in mind that 
extensive research is being pursued worldwide to use TRAIL or TRAIL 
derivatives in the clinic and that c-FLIP isoforms are often highly expressed in 
tumor cells,7 inhibiting c-FLIP solubility with locally applied or whole-body 
hyperthermia could be relevant to cancer TRAIL-based therapies.2, 17  
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Figure 1. Hyperthermia increases TRAIL induced cell death in a caspase-
dependent but mitochondrial-independent manner. 
(a)  Schematic representation of the protocol used to stimulate cells with TRAIL. 
Cells were either stimulated at 37°C for 6 h, or incubated in the presence (T + 
HS) or absence (HS) of His-TRAIL for 1 h at 42°C followed by a 5 h additional 
incubation at 37°C. (b) Indicated cancer cell lines were stimulated with 500 ng/ml 
His-TRAIL (TRAIL) or TRAIL and hyperthermia (T + HS) as described above and 
apoptosis was measured after 6 h after the onset of the stimulation by hoechst 
staining. (c) MDA-MB-231 cells were pre-incubated or not 30 min with 5 μM 
caspase inhibitor z-VAD and stimulated with 50 ng/ml His-TRAIL. Apoptosis was 
measured after 6 h by hoechst staining. (d) Five hundred MDA-MB-231 cells, 
plated overnight in a 6-well plate, were pre-incubated or not for 30 minutes with 
20 μM z-VAD prior stimulation or not with 500 ng/ml His-TRAIL at 37°C or in 
hyperthermic condition (HS) for 1 h and allowed to recover for a week at 37°C 
before staining with methylene blue. (e) MDA-MB-231 cells were stimulated or 
not with 500 ng/ml His-TRAIL as indicated for 2, 4 or 6 h and cytosolic or 
membrane fractions were isolated (see methods). Expression levels of indicated 
proteins were detected by immunoblotting. One representative blot is shown 
(n=3). (f) MDA-MB-231 cells were stimulated as described above with 50 ng/ml 
His-TRAIL and caspase activities were measured by luminometry 1 to 8 h after 
stimulation using caspase-3/7 (DEVD), caspase-8/10 (IETD) or caspase-9 
(LEHD) luminogenic substrates. (g) MDA-MB-231 cells were transfected with 
non-targeting (si-Nt), Caspase-9 (si-C9) or BID (si-BID) targeting siRNAs. 72 h 
after transfection, cells were stimulated or not with 100 ng/ml His-TRAIL and 
apoptosis was analysed after 6 h by Annexin V staining and flow cytometry. 
Caspase-9 and BID expression levels are shown on the right. (h) MDA-MB-231 
cells, transfected with an empty retroviral vector (Mock) or a vector encoding Bcl-
xL, were stimulated as above and apoptosis induced by the indicated stimuli was 
analyzed by Hoechst. Bcl-xL expression is shown on the right. (i) MDA-MB-231 
cells were transfected with a non-targeting (si-Nt) or Caspase-8 (si-C8) targeting 
siRNA, stimulated or not 72 h after transfection with 100 ng/ml His-TRAIL and 
apoptosis was analyzed as above. Caspase-8 expression levels were controlled 
by immunoblotting. (b, c, d, g, h and i) Error bars represent SD from at least 3 
independent experiments. 
 
 
 
 
Figure 2. Hyperthermia prevents FLIP recruitment to the TRAIL DISC.  
(a) MDA-MB-231 cells, stimulated with 500 ng/ml His-TRAIL at 42°C and/or at 
37°C for the indicated period of time, were lysed and the TRAIL DISC was 
immunoprecipitated using an anti-histidine antibody (see methods). DISC 
components associated with TRAIL were analyzed by immunoblotting as 
indicated. (b) MDA-MB-231 cells were stimulated as above and the initiator 
caspase-8 was immunoprecipitated. TRAIL DISC components were analyzed by 
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immunoblotting. Alternatively, an isotype control antibody (CTL-Ig) was used for 
specificity. NT stands for non-treated cell extracts. (a, b) One representative blot 
is shown (n=3). Black arrows show uncleaved proteins, white arrows indicate 
cleaved proteins. Grey arrow shows the short c-FLIP isoform. 
 
 
 
Figure 3. Hyperthermia-mediated cytosolic c-FLIP depletion is sufficient to 
sensitize tumor cells to TRAIL apoptosis. 
(a) MDA-MB-231 cells were treated with 500 ng/ml His-TRAIL or not (NT) for the 
indicated times and temperatures and c-FLIP expression was analysed from 
whole cell lysate (WCL) by immunoblotting together with caspase-8, -10 and 
FADD. HSC70 and HSP27 were used as loading and heat shock controls, 
respectively. Black arrows show uncleaved proteins, white arrows indicate 
cleaved proteins. Grey arrow shows the short c-FLIP isoform. (b) MDA-MB-231 
cells were stimulated as above and lysed in NP40 1% lysis buffer. After 
centrifugation, the supernatants (Soluble) and the pellets resuspended in a buffer 
containing 1% SDS (Insoluble), were loaded and indicated proteins were 
analysed by immunoblotting. (c, d) MDA-MB-231 cells were transfected with non-
targeting (si-Nt) or FLIP (si-FLIP) targeting siRNAs and stimulated 72 h after 
transfection with (c) 50 ng/ml or (d) increasing concentrations of His-TRAIL and 
apoptosis (Annexin V) was measured by flow cytometry. FLIP expression levels 
were controlled by immunoblotting. (e) MDA-MB-231 cells stably expressing c-
FLIPL or c-FLIPS or infected with an empty vector (Mock) were stimulated with 50 
ng/ml His-TRAIL as above and apoptosis (Annexin V) was measured by flow 
cytometry. FLIP expression levels were controlled by immunoblotting. (f) Stably 
expressing c-FLIPL or Mock-infected MDA-MB-231 cells were stimulated or not 
(NT) as indicated with 500 ng/ml His-TRAIL for 15 to 120 minutes and expression 
of c-FLIPL was analysed by immunoblotting in whole cell lysates (WCL), as well 
as cytosolic and insoluble NP40 detergent fractions, as described above. (g) 
MDA-MB-231 stably expressing c-FLIPL, c-FLIPS or mock-infected (Mock) cells 
were stimulated with 500 ng/ml His-TRAIL for 30 minutes at 37°C or at 42°C (T + 
HS) and caspase-8 was immunoprecipitated for analysis of TRAIL DISC 
composition by immunoblotting. (a, b, f, g) One representative blot is shown 
(n=3). 
 
 
Figure 4. Hyperthermia-induced c-FLIPL/S aggregation provokes c-FLIP 
depletion from the cytosol, thereby preventing its recruitment to the TRAIL 
DISC and enhancing apoptosis induced by TRAIL. 
(a) The lung carcinoma A549, the liver adenocarcinoma SK-HEP1, and the two 
colon carcinoma SW480 and HCT116 cell lines were incubated or not (NT) at 
42°C for 15 or 60 min and c-FLIPL expression was analysed in NP40 soluble and 
insoluble fractions by immunoblotting. (b) Schematic representation of the cell 
fractionation experiment performed in (c). MDA-MB-231 cells were lysed in 
NP40. Extracts were then either incubated on ice (0°C) or at 37°C for 60 min, or 
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incubated for 15 or 60 min at 42°C and soluble and insoluble fractions were 
separated by centrifugation to analyse FLIP expression levels by immunoblotting. 
(d) MDA-MB-231 cells were lysed in NP40 and incubated or not at 42°C for the 
indicated times in the presence or absence of increasing amounts of glycerol 
(expressed here as % v/v). Expression levels of c-FLIPL, caspase-8 and 
caspase-10 were analysed by immunoblotting. Actin was used as a loading 
control. (e and f) MDA-MB-231 or HCT116 cells were pre-incubated for 60 min 
with increasing amounts of glycerol. Cells were then lysed in NP40 and cell 
extracts were incubated or not at 42°C for 30 minutes and centrifuged to collect 
the soluble and the insoluble NP40 fractions. c-FLIP and caspase-8 content was 
analysed by immunoblotting. (g) MDA-MB-231 cells were pre-incubated as above 
in the presence of 5% glycerol and stimulated or not 6 h in the presence of 50 
ng/ml His-TRAIL at 37°C or 42°C (HS, see Figure 1a).  Apoptosis (Annexin V) 
was measured by flow cytometry. (h) MDA-MB-231 cells were stimulated with 
500 ng/ml His-TRAIL at 37°C or at 42°C (HS) in the presence or absence of 
glycerol (5% v/v) and TRAIL DISC was analyzed 2 h after the onset of the 
stimulation by immunoblotting after immunoprecipitation of the caspase-8. Black 
arrows show uncleaved proteins, white arrows indicate cleaved proteins. (a, c, d, 
e, f, h) One representative blot is shown (n=3). 
 
 
Materials and Methods  
 
Ligand production and chemicals  
 
His-tagged TRAIL and FasL were produced and used as described 
previously.52 Staurosporine, glycerol, nonidet P-40 (NP40) and sodium dodecyl 
sulfate (SDS) were purchased from Sigma-Aldrich (Lyon, France). Bax channel 
blocker was from Santa Cruz Biotechnology (Tebu-bio, Le Perray en Yvelines, 
France). MG-132 (Cat# 1748) was from Tocis (Bristol, United Kingdom). The 
pan-caspase inhibitor z-VAD-fmk and cycloheximide (Cat# ALX-380-269) were 
from Enzolife science (Villeurbanne, France).   
 
 
Antibodies  
For western blot analysis, anti-TRAIL-R1 (Cat# AB16955) and TRAIL-R2 (Cat# 
AB16942) were purchased from Chemicon (Millipore, Molsheim, France). Anti-
FADD (Cat# 610400) and RIP1 antibodies (Cat# 551041) were obtained from 
Transduction Laboratories (BD biosciences, Le Pont de Claix, France). Anti-
caspase-8 (clone 5F7) and caspase-10 (clone 4C1) antibodies were obtained 
from Medical & Biological Laboratories (Clinisciences, Montrouge, France). 
Antibodies against BID (Cat# 2002), caspase-3 (clone 8G10), cleaved caspase-9 
(clone Asp315), Histone H3 (clone D1H2), p-HSP27 S82 (clone D1H2), cleaved 
PARP (clone D65E10) and Vimentin (clone D21H3) were obtained from Cell 
Signaling (Millipore). Anti-caspase-8 (clone C20), GAPDH (clone 0411), HSC70 
(clone B-6), TNFR1 (clone H5), and Ubiquitin (clone P4D1) antibodies were from 
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Santa Cruz Biotechnology. Anti-FLIP (clone 7F10), HSP27 (clone G3.1), Anti-p-
HSP27 S15 (Cat# ADI-SPA-525), p-HSP27 S78 (Cat# ADI-SPA-523), HSP70 
(clone C92F3A-5) and HSP90β (clone K3705) antibodies were from Enzolife 
science. Anti-FLIP antibody (clone Dave-2) was from Adipogen (Coger, Paris, 
France). Anti-Bcl-xL (clone E18) and anti-HSP90α (clone D7a) antibodies were 
purchased from ABCAM (ABCAM, Paris, France). The anti-Histidine (clone 
AD1.1.10) was from AbD serotec (Bio-rad, Marnes-la-Coquette, France). HRP-
conjugated anti-rabbit or mouse antibodies were from Jackson ImmunoResearch 
(Interchim, Montluçon, France). HRP-conjugated anti-mouse IgG1, Ig2a and Ig2B 
specific antibodies were from Southern Biothech (Clinisciences). For ﬂow 
cytometry experiments, the anti-TRAIL-R1 (clone wB-K32), and TRAIL-R2 (clone 
B-L27), TRAIL-R3 (clone wB-B44) and TRAIL-R4 (clone wB-P30) antibodies 
were kindly provided by Diaclone (Besançon, France). The secondary antibody 
was an Alexa-488 coupled-goat anti-mouse from Molecular Probes (Life 
technologies, Saint Aubin, France).  
 
Cell culture 
MDA-MB-231 (human mammary adenocarcinoma), A549 (human lung 
adenocarcinoma), SK-HEP-1 (human hepatocellular carcinoma), DU145 (human 
prostate adenocarcinoma) and the two human colon adenocarcinomas HCT116 
and SW480 cell lines were cultured with high-glucose Dulbecco’s modiﬁed 
Eagle’s medium DMEM provided by Dutscher (Dutscher, Brumath, France) 
supplemented with 10% fetal bovine serum (Dutscher). PANC-1 (human 
pancreatic carcinoma) cell line was cultured in RPMI 1640 (Roswell Park 
Memorial Institute medium) provided by Dutscher and supplemented with 10% 
fetal bovine serum. All these cell lines were grown in an incubator at 37°C and 
5% CO2. 
 
Retrovirus production and cell transduction 
The retroviral vector pBABE-puro encoding Bcl-xL was kindly provided by Dr 
Jerry Chipuk (Icahn Medical Institute, New York, NY), WT VSV tagged c-FLIPL, 
and c-FLIPS have previously been described.
53 Mutated VSV-FLIPL were 
produced by site directed mutagenesis using pBABE-puro-WT-VSV-FLIPL and 
the following primers : K106R forward 5’-GAG-ATT-GGT-GAG-GAT-TTG-GAT-
AGA-TCT-GAT-GTG-TCC-TCA-TTA-AT-3’ reverse 5’-ATT-AAT-GAG-GAC-ACA-
TCA-GAT-CTA-TCC-AAA-TCC-TCA-CCA-ATC-TC-3’; T166A forward 5’-CAC-
AGA-ATA-GAC-CTG-AAG-GCA-AAA-ATC-CAG-AAG-TAC-AAG-3’ reverse 5’-
CTT-GTA-CTT-CTG-GAT-TTT-TGC-CTT-CAG-GTC-TAT-TCT-GTG-3’; T166D 
forward 5’-CAC-AGA-ATA-GAC-CTG-AAG-GAT-AAA-ATC-CAG-AAG-TAC-
AAG-C-3’ reverse 5’-GCT-TGT-ACT-TCT-GGA-TTT-TAT-CCT-TCA-GGT-CTA-
TTC-TGT-G-3’; K167R forward 5’-CAG-AAT-AGA-CCT-GAA-GAC-ACG-AAT-
CCA-GAA-GTA-CAA-GCA-G-3’ reverse 5’-CTG-CTT-GTA-CTT-CTG-GAT-TCG-
TGT-CTT-CAG-GTC-TAT-TCT-G-3’; T166A/K167R forward 5’-CCA-CAG-AAT-
AGA-CCT-GAA-GGC-ACG-AAT-CCA-GAA-GTA-CAA-GCA-G-3’ reverse 5’-
CTG-CTT-GTA-CTT-CTG-GAT-TCG-TGC-CTT-CAG-GTC-TAT-TCT-GTG-G-3’; 
T166D/K167R forward 5’-CAC-AGA-ATA-GAC-CTG-AAG-GAT-CGA-ATC-CAG-
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AAG-TAC-AAG-CAG-3’ reverse 5’-CTG-CTT-GTA-CTT-CTG-GAT-TCG-ATC-
CTT-CAG-GTC-TAT-TCT-GTG-3’; S193A forward 5’-GCA-GCA-ATC-CAA-AAG-
GCT-CTC-AAG-GAT-CCT-TCA-AAT-AAC-3’ reverse 5’-GTT-ATT-TGA-AGG-
ATC-CTT-GAG-AGC-CTT-TTG-GAT-TGC-TGC-3’; S193D forward 5’-GCA-GCA-
ATC-CAA-AAG-GAT-CTC-AAG-GAT-CCT-TCA-AAT-AAC-3’ reverse 5’-GTT-
ATT-TGA-AGG-ATC-CTT-GAG-ATC-CTT-TTG-GAT-TGC-TGC-3’; K195R 
forward 5’-CAA-GCA-GCA-ATC-CAA-AAG-AGT-CTC-AGG-GAT-CCT-TCA-AAT-
3’ reverse 5’-ATT-TGA-AGG-ATC-CCT-GAG-ACT-CTT-TTG-GAT-TGC-TGC-
TTG-3’; F114G forward 5’-TCT-GAT-GTG-TCC-TCA-TTA-ATT-GGC-CTC-ATG-
AAG-GAT-TAC-ATG-GGC-3’ reverse 5’-GCC-CAT-GTA-ATC-CTT-CAT-GAG-
GCC-AAT-TAA-TGA-GGA-CAC-ATC-AGA-3’; F114G/L115G  forward 5’-TCT-
GAT-GTG-TCC-TCA-TTA-ATT-GGC-GGC-ATG-AAG-GAT-TAC-ATG-GGC-3’ 
reverse 5’-GCC-CAT-GTA-ATC-CTT-CAT-GGG-CGG-AAT-TAA-TGA-GGA-
CAC-ATC-AGA-3’. All constructs were checked by sequencing and used to 
generate stably expressing FLIPL mutants as follows. Cells were transduced for 
16 h with viral supernatants containing polybrene (8 mg/ml), washed in PBS, and 
cultured in complete medium containing puromycin (2.5 μg/ml) obtained from 
Invivogen (Invivogen, Toulouse, France). 
 
Treatments with hyperthermia and TRAIL 
Cells were treated with the indicated concentration of His-TRAIL in supplemented 
DMEM and heated at 42°C for 1h or the indicated time in a preheated water bath 
or at 37°C in an incubator. Cells were then incubated for 5 h or the indicated time 
with 5% CO2 at 37°C before analysis. 
 
Hoechst analysis 
Apoptosis was assessed by Hoechst staining (20 µg/ml) and determination of the 
percentage of condensed and/or fragmented nuclei from at least 300 cells per 
conditions on 3 different fields. Experiments were repeated at least three times.  
 
Annexin V analysis 
Annexin V-FITC staining kit was purschased from Miltenyi Biotec (Miltenyi Biotec, 
Paris, France) and used according to the manufacturer’s instructions. Stained 
cells were analysed with a BD LSR2 flow cytometer (BD biosciences). The 
percentage of Annexin V-positive cells was calculated as the number of cells 
demonstrating Annexin V staining (PI negative or positive) divided by the total 
number of cells examined. Experiments were repeated at least three times. 
 
 
Caspases activity analysis 
103 cells were implanted in 96-well plates. 24 h after, cells were stimulated with 
50 ng/ml His-TRAIL at 37°C for the indicated time. Alternatively, cells were 
stimulated with TRAIL at 42°C for 1 h then were incubated or not at 37°C for the 
remaining time (1 to 7 h), before caspase activity analysis. Caspases -3/-7 
(DEVDase, Cat# G8090), Caspase-8 (IETDase, Cat# G8200) and Caspase-9 
(LHDase, Cat# G8210) activities were measured by luminometry with a 
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commercial kit obtained from Promega (Promega France, Charbonnière, France) 
according to the manufacturer’s protocol. Experiments were repeated at least 
three times. 
 
Gene silencing by siRNA.  
siRNA have been transfected with Interferin purshased from Polyplus (Polyplus 
transfection, Illkirch, France), according to the manufacturer’s protocol. siRNA 
directed against BID (Cat# L-004387-00), Caspase-9 (Cat# L-003309-00), 
Caspase-8 (Cat# L-003466-00), HSP90A (Cat# L-005186-00), HSP90B (Cat# L-
005187-00), RIP1 (Cat# L-004445-00), FLIP (Cat# L-003772-00) and non-
targeting (Cat# L-001810-10-05) were obtained from Dharmacon (Enzolife 
science). siRNA directed against HSP27 (Cat# AM16708) was purchased from 
Ambion (Life technologies). siRNA directed against HSP70 (Cat# 
SASI_Hs01_00051449) was purchased from Sigma-Aldrich. 
 
Immunoprecipitation 
For DISC analysis, 50 x 106 MDA-MB-231 cells per T175 cm2 flasks were 
stimulated with 12 ml of supplemented DMEM containing 500 ng/ml His-TRAIL 
for the indicated time and temperature. Cells were then washed with cold PBS, 
snap frozen and lysed with 1 ml lysis buffer containing 1% NP40, 20 mM Tris-HCl 
pH 7.5, 150 mM NaCl and 10% glycerol. Lysates were pre-cleared with 
Sepharose 6B (Sigma-Aldrich) for 1 h at 4°C with on a rotating wheel and then 
immunoprecipitated overnight with G-protein Sepharose beads (Cat# 17-0618-
01, GE Healthcare, Dutscher) in the presence of 2 μg of anti-Histidine, Caspase-
8 (clone C20) or corresponding Ig isotype control (CTL-Ig). Beads were then 
washed three times with 1x lysis buffer, and immunoprecipitates were eluted with 
SDS gel loading buffer (Tris-HCl 63 mM, SDS 1%, phenol red 0.03%, glycerol 
10% and DTT 100 mM of pH6.8), boiled for 5 min and processed for 
immunoblotting. 
 
Lysates and fractionation 
Cells were treated as indicated and washed in cold PBS. Whole cell lysis was 
performed using the SDS gel loading buffer. Samples were sonicated and boiled 
for 5 min before loading and immunoblotting analysis. For soluble/insoluble 
fractionation experiments, cells were lysed for 20 min on ice in a non ionic 
detergent containing buffer composed of 1% NP40, 20 mM Tris-HCl pH 7.5, 150 
mM NaCl and 10% glycerol. Lysates were then centrifuged 12 min at 10 000 rcf 
and supernatants (soluble fraction) or the pellet (insoluble fraction) were 
recovered in 1x final concentration of SDS gel loading buffer and processed as 
above for immunoblot analysis. Alternatively, for glycerol studies, NP40 
containing lysis buffer was used without or with increasing concentrations of 
glycerol as indicated. 
 
Western blotting 
Immunoprecipitates or cell lysates obtained from WCL or cell fractionation were 
resolved by SDS-PAGE and transferred to PVDF membranes (Amersham, 
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Biosciences, Les Ullis, France). Nonspeciﬁc binding sites were blocked by 
incubating membranes for 1 h in PBS containing 0.01% of Tween 20 and 5% 
(w/v) dried skimmed milk (PBS-Tm). Immunoblots were then incubated with 
speciﬁc primary antibody diluted in PBS-Tm for 2 h at room temperature or 
overnight at 4°C, washed three times in PBS-T for 10 minutes. Membranes were 
then incubated with corresponding HRP-conjugated secondary antibody in PBS-
T for 1 h and washed three times followed by a chemiluminescence detection 
with the Western Bright Quantum kit (Advansta, Menlo Park, CA). Protein 
expression levels were detected with ChemiDoc MP gel imager (Bio-Rad) or 
using x-ray films. 
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